Newsround
Selected reports by Janet Fricker Download full article
December 2011
To cut or not to cut? Why surgeons don’t have all the answers
Years ago, surgery was the principal way of treating most cancers. Nowadays, surgery has become more conservative as the concept of operability is changing. Download full article
Luzia Travado: improving outcomes for patients by attending to their distress
Luzia Travado’s determination to improve the psychosocial care for cancer patients has made her a familiar face across Europe and beyond. Download full article
Prognostic and predictive markers in colorectal cancer: implications for clinical management
Efforts to find genetic patterns may offer the basis for identifying subgroups of colorectal cancer similar to those now used in breast cancer. Download full article
Hope for me, and for others who come after: Victoria Lambert’s award-winning article explores the impact of a new network of early trial centres
Delays in getting promising new treatments into trials are slowing progress in cancer care and failing patients who have run out of options and are running out of time. Download full article
Redefining the role of pathology: how Giuseppe Viale embraced the new responsibilities of the molecular era
In the era of personalised therapies, complete and accurate pathology reports are vital. Giuseppe Viale is helping pathologists rise to their new responsibilities and ensuring they are given the opportunity to play a full role. [more]
An important piece of the localised prostate cancer puzzle?
Download full article
Taking the first step on the road to cancer control
The UN Summit on Non-Communicable Diseases opened a window of opportunity for decisive action to set poorer countries on the road towards sustainable cancer control. Download full article
Front-line therapy in lung cancer with mutations in EGFR
Large randomised phase III trials conducted in patients with non-small-cell lung cancer (NSCLC) harbouring activating mutations in EGFR have demonstrated that erlotinib or gefitinib are superior to platinum-based chemotherapy. Download full article